

Special Issue

Aortic Aneurysm: Mechanisms, Biomarkers, and Therapeutic Strategy

Message from the Guest Editors

This Special Issue of *Biomedicines*, titled “Aortic Aneurysm: Mechanisms, Biomarkers, and Therapeutic Strategy”, aims to showcase cutting-edge basic, translational, and clinical research that advances our understanding of the molecular, cellular, and biomechanical underpinnings of aortic aneurysm. In addition, it will highlight innovations in diagnosis, risk stratification, and therapeutics. We welcome contributions from diverse fields, including vascular biology, genetics, molecular medicine, biomechanics, pharmacology, and surgery. We emphasize the importance of an integrative approach to this complex disease utilizing in vitro, ex vivo, and in vivo experimental models. This Special Issue strives to convene a global community of researchers and clinicians dedicated to unraveling the complexities of aortic aneurysm disease and paving the way toward innovative, patient-centered care. We cordially invite you to contribute your latest findings and insights to this Special Issue and help shape the future of aortic aneurysm research and treatment.

Guest Editors

Dr. Mitra Esfandiarei

1. Biomedical Sciences Program, College of Graduate Studies,
Midwestern University, Glendale, AZ 85308, USA
2. College of Medicine Phoenix, University of Arizona, Phoenix, AZ
85004, USA

Dr. Seda Selamet Tierney

Vascular Research Laboratory, Stanford Medicine Heart Center,
Division of Cardiology, Stanford University, Stanford, CA 94305, USA

Deadline for manuscript submissions

31 March 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/253003

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).